An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs

Expert Opinion on Drug Discovery

Volumn 12, Issue 6, 2017, Pages 625-633

  Kim, Wooseong ^a   Hendricks, Gabriel Lambert ^a   Lee, Kiho ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

antibiotics; Caenorhabditis elegans; drug discovery; high throughput screen

Indexed keywords

3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; 3 (PEHNYLSULFONYL) W PYRAZINECARBONITRILE; ANTIINFECTIVE AGENT; CLOSANTEL; FLUOROURACIL; IMMUNOMODULATING AGENT; NH 125; NICLOSAMIDE; OXYCLOZANIDE; RPW 24; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

CAENORHABDITIS ELEGANS; DRUG SCREENING; ENTEROCOCCUS FAECALIS; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIUM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CAENORHABDITIS ELEGANS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS;

EID: 85019177423     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1319358     Document Type: Review

References (85)

1. Lewis K., Platforms for antibiotic discovery. Nat Rev Drug Discov. 2013;12:371–387.•• Considered expert in the field, Lewis provides a review of new antibiotic discovery strategies.
2. Brown ED, Wright GD., Antibacterial drug discovery in the resistance era. Nature. 2016;529:336–343.
3. Kolter R, van Wezel GP. Goodbye to brute force in antibiotic discovery? Nat Microbiol. 2016;1:15020.
4. Schatz A, Bugle E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc Soc Exp Biol Med. 1944;55:66–69.
5. Wong KK, Kuo DW, Chabin RM, et al. Engineering a cell-free murein biosynthetic pathway:combinatorial enzymology in drug discovery. J Am Chem Soc. 1998;120:13527–13528.
6. Throup JP, Koretke KK, Bryant AP, et al. A genomic analysis of two-component signal transduction in Streptococcus pneumoniae. Mol Microbiol. 2000;35:566–576.
7. Ji Y, Zhang B, van SF, et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science. 2001;293:2266–2269.
8. Jarvest RL, Berge JM, Berry V, et al. Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against Gram-positive pathogens. J Med Chem. 2002;45:1959–1962.
9. Payne DJ, Miller WH, Berry V, et al. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob Agents Chemother. 2002;46:3118–3124.
10. DeVito JA, Mills JA, Liu VG, et al. An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol. 2002;20:478–483.
11. Yin D, Fox B, Lonetto ML, et al. Identification of antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics. 2004;5:101–113.
12. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004;432:855–861.
13. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs:confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40.
14. Wright GD. The antibiotic resistome:the nexus of chemical and genetic diversity. Nat Rev Microbiol. 2007;5:175–186.
15. Chambers HF, DeLeo FR. Waves of resistance:Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629–641.
16. Stryjewski ME, Corey GR. Methicillin-resistant Staphylococcus aureus:an evolving pathogen. Clin Infect Dis. 2014;58(Suppl 1):SS10–SS19.
17. Lewis K. Persister cells. Annu Rev Microbiol. 2010;64:357–372.• The author provides an excellent review of bacterial persisters.
18. Brauner A, Fridman O, Gefen O, et al. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–330.
19. Bigger JW. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. The Lancet. 1944;244:497–500.
20. Keren I, Kaldalu N, Spoering A, et al. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230:13–18.
21. Keren I, Shah D, Spoering A, et al. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol. 2004;186:8172–8180.
22. Gefen O, Gabay C, Mumcuoglu M, et al. Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria. Proc Natl Acad Sci U S A. 2008;105:6145–6149.
23. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature. 2011;473:216–220.
24. Conlon BP, Nakayasu ES, Fleck LE, et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503:365–370.
25. Casadevall A, Pirofski LA. Host-pathogen interactions:redefining the basic concepts of virulence and pathogenicity. Infect Immun. 1999;67:3703–3713.
26. Moy TI, Ball AR, Anklesaria Z, et al. Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A. 2006;103:10414–10419.•• This is the first report of using C. elegans-infection models for anti-infective drug discovery.
27. Moy TI, Conery AL, Larkins-Ford J, et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol. 2009;4:527–533.
28. Timmons L, Fire A. Specific interference by ingested dsRNA. Nature. 1998;395:854–854.• This is the first report that gene knockout can be achieved by feeding worms with bacteria expressing dsRNA.
29. Kamath R. Genome-wide RNAi screening in Caenorhabditis elegans. Methods. 2003;30:313–321.
30. Rual J-F, Ceron J, Koreth J, et al. Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNAi library. Genome Res. 2004;14:2162–2168.
31. Nollen EAA, Garcia SM, van Haaften G, et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A. 2004;101:6403–6408.
32. van Haaften G, Vastenhouw NL, Nollen EAA, et al. Gene interactions in the DNA damage-response pathway identified by genome-wide RNA-interference analysis of synthetic lethality. Proc Natl Acad Sci U S A. 2004;101:12992–12996.
33. Ben L, Crombie C, Tischler J, et al. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat Genet. 2006;38:896–903.
34. Lehner B, Tischler J, Fraser AG. RNAi screens in Caenorhabditis elegans in a 96-well liquid format and their application to the systematic identification of genetic interactions. Nat Protoc. 2006;1:1617–1620.
35. O’Reilly LP, Knoerdel RR, Silverman GA, et al. High-throughput, liquid-based genome-wide RNAi screening in C. elegans. Methods Mol Biol. 2016;1470:151–162.
36. Irazoqui JE, Urbach JM, Ausubel FM. Evolution of host innate defence:insights from Caenorhabditis elegans and primitive invertebrates. Nat Rev Immunol. 2010;10:47–58.•• This review summarizes the main C. elegans immune signaling pathways and their evolutionary conservation and diversion between C. elegans and mammals.
37. Nijman SMB. Synthetic lethality:general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011;585:1–6.
38. Kirienko DR, Revtovich AV, Kirienko NV. A high-content, phenotypic screen identifies fluorouridine as an Inhibitor of pyoverdine biosynthesis and Pseudomonas aeruginosa virulence. Msphere. 2016;1:e00217–16.•• The authors report the first anti-virulence agents discovered in a C. elegans-P. aeruginosa infection HTS.
39. Rajamuthiah R, Fuchs BB, Jayamani E, et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. Plos ONE. 2014;9:e89189.
40. Jayamani E, Rajamuthiah R, Larkins-Ford J, et al. Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrob Agents Chemother. 2015;59:1728–1737.
41. Pujol N, Zugasti O, Wong D, et al. Anti-fungal innate immunity in C. elegans is enhanced by evolutionary diversification of antimicrobial peptides. Plos Pathog. 2008;4:e1000105.
42. Mylonakis E, Ausubel FM, Perfect JR, et al. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A. 2002;99:15675–15680.
43. Couillault C, Pujol N, Reboul J, et al. TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol. 2004;5:488–494.
44. Peleg AY, Tampakakis E, Fuchs BB, et al. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2008;105:14585–14590.
45. Okoli I, Coleman JJ, Tampakakis E, et al. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. Plos ONE. 2009;4:e7025.
46. Fuchs BB, Rajamuthiah R, Souza ACR, et al. Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med Chem. 2016;8:117–132.
47. Sun L, Liao K, Wang D. Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans. Plos ONE. 2015;10:e0117695.
48. Breger J, Fuchs BB, Aperis G, et al. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. Plos Pathog. 2007;3:e18.
49. Tampakakis E, Okoli I, Mylonakis E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nat Protoc. 2008;3:1925–1931.
50. Muhammed M, Arvanitis M, Mylonakis E. Whole animal HTS of small molecules for antifungal compounds. Expert Opin Drug Discov.Taylor & Francis. 2016;11:177–184.
51. Kim W, Conery AL, Rajamuthiah R, et al. Identification of an antimicrobial agent effective against methicillin-resistant Staphylococcus aureus persisters using a fluorescence-based screening strategy. Plos ONE. 2015;10:e0127640.•• The authors demonstrate that MOA of hits from the C. elegans-MRSA can be elucidated by a subsequent target-based screen.
52. Rajamuthiah R, Jayamani E, Majed H, et al. Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorg Med Chem Lett. 2015;25:5203–5207.
53. Garigan D, Hsu A-L, Fraser AG, et al. Genetic analysis of tissue aging in Caenorhabditis elegans:a role for heat-shock factor and bacterial proliferation. Genetics. 2002;161:1101–1112.
54. Tan MW, Mahajan-Miklos S, Ausubel FM. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci U S A. 1999;96:715–720.• The authors provide evidence that C. elegans can be a model organism for bacterial pathogenesis.
55. Mahajan-Miklos S, Tan MW, Rahme LG, et al. Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell. 1999;96:47–56.• The authors provides evidence that C. elegans can be a model organism for bacterial pathogenesis.
56. Tan MW, Rahme LG, Sternberg JA, et al. Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A. 1999;96:2408–2413.• The authors demonstrate that bacterial virulence factors results in killing of C. elegans.
57. Kim DH, Feinbaum R, Alloing G, et al. A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science. 2002;297:623–626.• This is the first report of a highly conserved, crucial immune signaling p38 MAPK pathway in C. elegans that is highly conserved with the mammalian pathway.
58. Mallo GV, Kurz CL, Couillault C, et al. Inducible antibacterial defense system in C. elegans. Curr Biol. 2002;12:1209–1214.
59. Garsin DA, Sifri CD, Mylonakis E, et al. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci U S A. 2001;98:10892–10897.
60. Sifri CD, Begun J, Ausubel FM. The worm has turned-microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol. 2005;13:119–127.
61. Troemel ER, Chu SW, Reinke V, et al. p38 MAPK regulates expression of immune response genes and contributes to longevity in C. elegans. Plos Genet. 2006;2:e183.
62. Garsin DA, Villanueva JM, Begun J, et al. Long-lived C. elegans daf-2 mutants are resistant to bacterial pathogens. Science. 2003;300:1921–1921.
63. Ashburn TT, Thor KB. Drug repositioning:identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.
64. Aubé J. Drug repurposing and the medicinal chemist. ACS Med Chem Lett. 2012;3:442–444.
65. Rajamuthiah R, Fuchs BB, Conery AL, et al. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. Plos ONE. 2015;10:e0124595.
66. Johnston T, Hendricks GL, Shen S, et al. Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin. Future Med Chem. 2016;8:1941–1952.
67. Yamamoto K, Kitayama T, Ishida N, et al. Identification and characterization of a potent antibacterial agent, NH125 against drug-resistant bacteria. Biosci Biotechnol Biochem. 2000;64:919–923.
68. Yamamoto K, Kitayama T, Minagawa S, et al. Antibacterial agents that inhibit histidine protein kinase YycG of Bacillus subtilis. Biosci Biotechnol Biochem. 2001;65:2306–2310.
69. Kim W, Fricke N, Conery AL, et al. NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption. Future Med Chem. 2016;8:257–269.
70. Pukkila-Worley R, Feinbaum R, Kirienko NV, et al. Stimulation of host immune defenses by a small molecule protects C. elegans from Bacterial Infection. Plos Genet. 2012;8:e1002733.•• The authors report the first ever immune-modulator discovered in a C. elegans-E. faecalis infection HTS.
71. Rutherford ST, Bassler BL. Bacterial quorum sensing:its role in virulence and possibilities for its control. Cold Spring Harb Perspect Med. 2012;2:a012427–a012427.
72. Ramachandran G. Gram-positive and gram-negative bacterial toxins in sepsis. Virulence. 2013;5:213–218.
73. Kirienko NV, Kirienko DR, Larkins-Ford J, et al. Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death. Cell Host and Microbe. 2013;13:406–416.
74. Imperi F, Massai F, Facchini M, et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc Natl Acad Sci U S A. 2013;110:7458–7463.
75. Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB:a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57.
76. Gotoh O. Divergent structures of Caenorhabditis elegans cytochrome P450 genes suggest the frequent loss and gain of introns during the evolution of nematodes. Mol Biol Evol. 1998;15:1447–1459.
77. Harlow PH, Perry SJ, Widdison S, et al. The nematode Caenorhabditis elegans as a tool to predict chemical activity on mammalian development and identify mechanisms influencing toxicological outcome. Sci Rep. 2016;6:22965.
78. Dong H, Haining RL, Thummel KE, et al. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000;28:1397–1400.
79. Miyamoto J. Studies on the mode of action of organophosphorus compounds. Agr Biol Chem. 1964;28:411–430.
80. Roh J-Y, Choi J. Cyp35a2 gene expression is involved in toxicity of fenitrothion in the soil nematode Caenorhabditis elegans. Chemosphere. 2011;84:1356–1361.
81. Frearson JA, Collie IT. HTS and hit finding in academia–from chemical genomics to drug discovery. Drug Discov Today. 2009;14:1150–1158.
82. Pasquina LW, Santa Maria JP, Walker S. Teichoic acid biosynthesis as an antibiotic target. Curr Opin Microbiol. 2013;16:531–537.
83. Swoboda JG, Meredith TC, Campbell J, et al. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus. ACS Chem Biol. 2009;4:875–883.
84. Richter SG, Elli D, Kim HK, et al. Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria. Proc Natl Acad Sci U S A. 2013;110:3531–3536.
85. Hurdle JG, O’Neill AJ, Chopra I, et al. Targeting bacterial membrane function:an underexploited mechanism for treating persistent infections. Nat Rev Microbiol. 2011;9:62–75.